Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus hypofractionated radiotherapy for unfit esophageal cancer patients
NL-OMON57178Phase 2Completed
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in esophageal cancer, sponsored by Vrije University Medical Center. Primary endpoint: Feasibility of the regimen. Started Jul 2021; status: completed.
02
Drugs
capecitabine
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NL-OMON57178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57178.